Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells

We developed core-shell nanoparticles incorporating the α4β7 monoclonal antibody (mAb) for selectively delivering therapeutic agents to gut-homing T cells in the gut-associated lymphoid tissue (GALT), while simultaneously blocking HIV infection. We demonstrate enhanced antiretroviral activity of a protease inhibitor and α4β7 mAb combination in vitro, and show targeting function in rhesus macaque primary cells and in mice. These data demonstrate that our LCNP delivery system has the potential to co-deliver ARV drugs and mAbs to anatomical and cellular HIV reservoirs for the purpose of reducing reservoir size and potentially eradicating the virus.357